NASDAQ · BTAI
Healthcare · Biotechnology
$0.07
Up+$0.03 (+64.22%)
Updated Oct 6, 2026, 6:02 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BTAI
1M range · 0 trading sessions · Daily adjusted prices
BTAI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BTAI.
Company
Market Activity
Research & News
BTAI research
Company profile and research snapshot.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | Rodman & Renshaw | Buy | — |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 12, 2025 | Mizuho | Neutral | — |
No generated briefing is available yet.
Benzinga · Sep 4, 2026
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock moved upwards by
ChartMill · Sep 4, 2026
Unusual volume stocks are being observed in Friday's session.
Yahoo · Sep 4, 2026
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]
Benzinga · Sep 4, 2026
Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies (NASDAQ:BIAF) shares
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BTAI.
